MSC Hydrogel Composition With HPMC for Cell Viability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hydrogel compositions for treating diseases, particularly lupus and kidney fibrosis, do not effectively improve cell viability and therapeutic potential, and the addition of certain excipients can even degrade their characteristics.
Innovation Solution
Hydrogel compositions comprising hyaluronic acid, hydroxypropyl methyl cellulose (HPMC), and mesenchymal stromal cells (MSCs) are formulated to enhance cell viability and therapeutic efficacy, with HPMC improving the hydrogel's characteristics and therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If certain excipients are added to hydrogel compositions, then the hydrogel characteristics may be improved, but the excipients can degrade the therapeutic potential and cell viability
Solution Approach 1:
Hyaluronic acid serves as an intermediary substance that supports mesenchymal stromal cell viability and function within the hydrogel matrix. It mediates between the hydrogel structure and the therapeutic cells, providing a biocompatible environment that enhances rather than degrades therapeutic potential.
Solution Approach 2:
The invention creates a composite hydrogel material combining hyaluronic acid with mesenchymal stromal cells and selective excipients (like HPMC at optimized concentrations). This composite approach allows the material to simultaneously provide structural integrity and enhance cell viability, resolving the contradiction between manufacturability and therapeutic reliability.
2Reliability
If the hydrogel composition is optimized for cell viability, then therapeutic efficacy is improved, but the formulation complexity increases
Solution Approach 1:
The invention optimizes specific formulation parameters, particularly HPMC concentration (0.01-0.1% w/v), to enhance cell viability. By carefully controlling these parameters within specific ranges, the formulation achieves high therapeutic efficacy without excessive complexity, as the optimization focuses on key critical parameters rather than numerous variables.
3Reliability
If HPMC is added to the hydrogel composition, then cell viability and therapeutic potential are enhanced, but the manufacturing precision requirements increase
Solution Approach 1:
HPMC is incorporated at specifically optimized low concentrations (0.01-0.1% w/v) that enhance cell viability while minimizing impacts on manufacturing precision. This parameter optimization allows the excipient to provide therapeutic benefits without requiring extreme manufacturing precision, as the effective concentration range is broad enough to accommodate normal manufacturing variations.
Data Source
AI summary
Described herein are hydrogel compositions comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.Additionally described herein are compositions for treatment, and methods for treatment of a disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.